These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24482781)

  • 1. The utility of human challenge studies in vaccine development: lessons learned from cholera.
    Shirley DA; McArthur MA
    Vaccine (Auckl); 2011 Oct; 2011(1):3-13. PubMed ID: 24482781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea.
    Ahmed T; Bhuiyan TR; Zaman K; Sinclair D; Qadri F
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD009029. PubMed ID: 23828581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
    Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
    Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Challenge clinical trial for evaluation of a vaccine candidate strain against cholera].
    Díaz Jidy M; Pérez Rodríguez A; Fernández Llanes R; Bravo Fariñas L; García Sánchez H; Valera Fernández R; García Imia L; Fando Calzada R; Menéndez Hernández J
    Rev Cubana Med Trop; 2010; 62(3):194-9. PubMed ID: 23437548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a live oral cholera vaccine in human volunteers.
    Woodward WE; Gilman RH; Hornick RB; Libonati JP; Cash RA
    Dev Biol Stand; 1976; 33():108-12. PubMed ID: 782960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cholera update and vaccination problems].
    Fournier JM; Villeneuve S
    Med Trop (Mars); 1998; 58(2 Suppl):32-5. PubMed ID: 9812307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.
    Levine MM; Kaper JB; Black RE; Clements ML
    Microbiol Rev; 1983 Dec; 47(4):510-50. PubMed ID: 6363898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.
    Black RE; Levine MM; Clements ML; Young CR; Svennerholm AM; Holmgren J
    Infect Immun; 1987 May; 55(5):1116-20. PubMed ID: 3552989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRELIMINARY STUDIES ON THE DEVELOPMENT OF A LIVE ORAL VACCINE FOR ANTI-CHOLERA IMMUNIZATION.
    MUKERJEE S
    Bull World Health Organ; 1963; 29(6):753-66. PubMed ID: 14107748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.
    Tacket CO; Forrest B; Morona R; Attridge SR; LaBrooy J; Tall BD; Reymann M; Rowley D; Levine MM
    Infect Immun; 1990 Jun; 58(6):1620-7. PubMed ID: 1692807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139.
    Cohen MB; Giannella RA; Losonsky GA; Lang DR; Parker S; Hawkins JA; Gunther C; Schiff GA
    Infect Immun; 1999 Dec; 67(12):6346-9. PubMed ID: 10569748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The state-of-the-art of approved and under-development cholera vaccines.
    Pastor M; Pedraz JL; Esquisabel A
    Vaccine; 2013 Aug; 31(38):4069-78. PubMed ID: 23845813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.
    Coster TS; Killeen KP; Waldor MK; Beattie DT; Spriggs DR; Kenner JR; Trofa A; Sadoff JC; Mekalanos JJ; Taylor DN
    Lancet; 1995 Apr; 345(8955):949-52. PubMed ID: 7715293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of improved attenuated and nucleic acid vaccines for heartwater.
    Collins NE; Pretorius A; van Kleef M; Brayton KA; Allsopp MT; Zweygarth E; Allsopp BA
    Dev Biol (Basel); 2003; 114():121-36. PubMed ID: 14677683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
    Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
    PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.